XOMA XOMA Corp
- 25.590
- -0.180-0.70%
XOMA Corp News
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual
XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss
Express News | XOMA Corp : Leerink Partners Raises Target Price to $42 From $40
Express News | XOMA Q1 2024 GAAP EPS $(0.86) Misses $(0.81) Estimate
Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M
07:41 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M
10-Q: Quarterly report
Express News | XOMA Corp: Net Loss for Q1 of 2024 Was $8.6 Mln, Compared to a Net Loss of $9.8 Mln for Q1 of 2023
XOMA 1Q Loss/Shr 86c >XOMA
XOMA 1Q Loss/Shr 86c >XOMA
XOMA 1Q Rev $1.49M >XOMA
XOMA 1Q Rev $1.49M >XOMA
Express News | XOMA Corp: Launched Xoma's First Stock Repurchase Program for up to $50 Mln
Express News | XOMA Q1 Net Income USD -8.6 Million
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
The market expects Xoma (XOMA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024.
Xoma Has Acquired An Economic Interest In Three Women's Health Assets From Daré Bioscience For An Upfront Payment Of $22M
Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023.XOMA further expands its late-stage portfolio with synthetic royalty and milestone i
Express News | XOMA Corp: Entitled to Potential Milestone Payments Based on Commercial Success of Xaciato
Express News | XOMA Corp: Will Receive Remaining Royalties Related to Xaciato™ Not Already Included in Daré's December 2023 Royalty-Backed Financing Agreement
Express News | XOMA Corp: Provided $22 Mln Upfront as Non-Dilutive Royalty Capital Solution to Daré Bioscience
Express News | XOMA:Adds Economic Interests in 3 First-in-Category Assets to Royalty and Milestone Portfolio Including Xaciato (Clindamycin Phosphate) Vaginal Gel 2%
XOMA Adds Economic Interests in Three First-in-Category Assets to Its Royalty and Milestone Portfolio Including XACIATO (Clindamycin Phosphate) Vaginal Gel 2%
Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in
Cracking The Code: Understanding Analyst Reviews For XOMA
4 analysts have expressed a variety of opinions on XOMA (NASDAQ:XOMA) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table provides a quick overview of
Analysis
Price Target
No Data
